A Phase 2 interventional study of Devil Claw and Placebo in Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by University of Southampton. Terminated at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-09-12.
Sponsored by University of Southampton · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Osteoarthritis, Knee with a site in United Kingdom — 12 open to participants now, 21 under way, none of them phase 3. Osteoarthritis, Knee · United Kingdom.
Among the 112 studies in Osteoarthritis, Knee with a site in United Kingdom, this one is the 51st largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2004, is one of 10 in phase 2, and was the 7th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →12 of the 112 studies in Osteoarthritis, Knee with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 18+
Golden Jubilee National Hospital · Sites in United Kingdom
Ages 18+
Middlesex University · Sites in United Kingdom
Ages 18+
Scarcell Therapeutics S.A.S. · Sites in United Kingdom
Ages 40+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 15 · Phase 4 9
First in 1999; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 80 across the 90 interventional studies, 150 across the 21 observational. Of the 78 that completed or were terminated, 23 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 112 have an industry lead sponsor. The 10 most frequent:
University of Southampton is the lead sponsor of 123 studies on the registry; 18 are open to participants now.
University of Southampton has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
6 of the studies in Osteoarthritis, Knee with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550024CrannMedSakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | 2026-12 |
| NCT06483191Belfast Health and Social Care TrustIMProving Outcomes With ACT After Knee Surgery | 2026-12 |
| NCT05675618Hospital for Special Surgery, New YorkReturn to Golf After Orthopaedic Surgery | 2026-12 |
| NCT06690710Scarcell Therapeutics S.A.S.FiH Safety and Feasibility Study Assessing Intra-articular Administration of aeGF in Patients With Knee Osteoarthritis | 2027-02-01 |
| NCT06885372Western University, CanadaLong-term Follow up of the Stability 1 Trial | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 112 studies in Osteoarthritis, Knee with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Osteoarthritis of both the knee and hip joints are common conditions; knee osteoarthritis affects 6% of adults over 30 years of age and osteoarthritis of the hip affects between 3% and 6% of the Caucasian population. Both forms of osteoarthritis are associated with disability. Conventional treatment (analgesics and the use non-steroidal anti-inflammatory, NSAIDS) is prophylactic, aimed at decreasing pain and improving function. However long term use of NSAIDS is associated with a high incidence of adverse events (gastrointestinal tract symptoms). A safer alternative treatment would therefore be beneficial.
Both anecdotal evidence and recent studies have implicated the potential of the herbal remedy Devil's Claw (Harpagophytum procumbens) for the treatment of painful, chronic arthritic type conditions (Ernst and Chrubasik, 2000). Devil's Claw is an extract obtained from the root of the Harpagophytum procumbens plant, a member of the sesame family found in the Kalahari region in South Africa. It has been shown that this herbal remedy has anti-inflammatory and analgesic effects (Baghdikian et al, 1997). Currently Devil's Claw is marketed for use as a supportive treatment of degenerative arthrosis, is not a Medicines Control Agency licensed product and is freely available to the general public in health food stores and pharmacies.
The objectives of this study are to assess the efficacy, optimum dosage and safety of the herbal remedy Devil's Claw (Harpagophytum) in the treatment of osteoarthritis of the knee and/or hip. The primary objective of this study is to investigate the following three principal questions:
These objectives are based on the following hypotheses :
Hypotheses
STUDY DESIGN: Randomized, placebo-controlled, dose-ranging two-centre study PREPARATIONS FOR INVESTIGATION: Devil's Claw (Allya®)/placebo as tablets
STATISTICAL METHODS:
Analysis on an intention to treat basis.
The following tests will be performed and all statistical significance will be set at p \< 0.05:
Primary efficacy analysis: The primary outcome will be the reduction in WOMAC total score from baseline to week 16. The week 16 means for the four treatment groups will be compared using an analysis of covariance taking account of baseline assessments and any demographic differences, age, gender, etc, which are found to be significant. Multiple comparison tests will be used to examine specific differences of initially specified interest, such as the two highest doses of Devil's Claw versus placebo.
Secondary Efficacy Analysis: Similar analyses of covariance will be used to examine treatment group differences at week 16 compared with baseline for WOMAC subscales (pain, stiffness and physical function), and Quality of Life assessments (SF-36). Changes in the subject's well-being and overall global assessment will be compared using appropriate non-parametric tests, e.g. Mann-Whitney test or MacNemar's test. Changes in attitudes and health beliefs to CAM will be assessed using Chi-Squared tests.
Safety Evaluation: Group differences between adverse event reporting will be assessed by descriptive methods.
NUMBER OF PATIENTS:
264 (50 patients in each group, with an expected total of 64 drop-outs) NUMBER OF SITES: 2
TIME SCHEDULE:
Study Start: April 2004 Study End: March 2007 Observation period/patient: 20 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with either a pragmatic diagnosis of osteoarthritis of the knee, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for knee OA1):
osteoarthritis of the hip, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for hip OA2):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sub clinical dose if the 3 doses employed
Drug: Devil Claw
Active dose
Drug: Devil Claw
Active dose
Drug: Devil Claw
Comparator for all active intervention arms
Drug: Placebo
Dose ranging study so will elucidate dose Frequency is four times daily
Also known as: Harpagophytum procumbens
Placebo has same dosing freq as for active intervention and for same time period
Western Ontario and Mc Master University OA Index (WOMAC)
WOMAC is a disease specific outcome measure for osteoarthritis. It has three subscales assessing pain (5 questions), stiffness (2 questions) and function (15 questions). together the subscales give an overall total score ranging from 0 (worst) to 100 (best; an increase in total score indicates an improvement in health. THe outcome was measured at baseline, week 8 and week 16. In this study the primary outcome was the reduction in WOMAC total score from baseline to the end of treatment at week 16.
Time frame: Baseline, week 8 and week 16
Pain Subscale on Western Ontario and Mc Master University OA Index
Subscale assessed by 100mm VAS based on five questions addressing pain in osteoarthritis using the terminators no pain (0mm) to extreme pain (100mm). a higher score therefore indicates more severe pain. This outcome was recorded at baseline, week 8 and week 16 (end of treatment). The outcome for this study was reported as the change in WOMAC pain score from baseline to end of treatment at week 16.
Time frame: Baseline, week 8 and week 16
Disability Subscale on The Western Ontario and Mc Master University OA Index
Subscale assessed by 100mm VAS based on twelve questions addressing disability in osteoarthritis with a higher score indicating worse symptoms. The VAS used terminators of no disability (0mm) to extreme disability (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.
Time frame: baseline, 8 and 16 weeks
Stiffness Subscale on the The Western Ontario and Mc Master University OA Index
Subscale assessed by 100mm VAS based on two questions addressing stiffness in osteoarthritis;a higher score indicating worse symptoms. The VAS used terminators of no stiffness (0mm) to extreme stiffness (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.
Time frame: Baseline, week 8 and week 16
Short Form-36 (SF-36)
Quality of Life assessment containing 8 scales clustered into 2 summary scales: physical health and mental health. Each question is scored out from 0 (indicating worst health) to 100 (indicating best health). Mean scores for the 8 scales (total scores/no questions completed) are calculated to give a total score for each of the two summary scales between 0 (worst health) and 100 (best health). SF36 was recorded at baseline, week 8 and at the end of treatment at week 16. we reported the change from baseline to end of treatment as the outcome.
Time frame: Baseline, week 8 and week 16
Patient Global Assessment
To assess changes in the subject's well-being based on 7 point likert scale ranging from very poor (0 point) to very good (7 point). Outcome was recorded at baseline, week 8 and end of treatment at week 16. We reported outcome as the change in patient global assessment from baseline to end of treatment at week 16.
Time frame: Baseline, week 8 and week 16
Complementary and Alternative Medicine Beliefs Inventory
Questionnaire to assess changes in attitudes and health beliefs to CAM.the questionnaire as 17 questions, each scored on a 7 point likert scale from strongly disagree to strongly agree; a higher score indicates stronger belief in the measure. Minimum score 17, maximum score 119
Time frame: four monthly
Adverse Event Reporting
To identify Group differences between the number of adverse event recorded by patient for both serious and non serious adverse events, as well as events considered being attributable to the study medication.
Time frame: Baseline and weeks 2,4,6,8,12 and 16
Recruited during 2004 to 2007 Recruitment location: From GP clinics and from adverts in the media
| Milestone | 240mg Devil Claw | 960mg/d Devil Claw | 1,920mg/d Devil Claw | Placebo |
|---|---|---|---|---|
| Started | 15 | 19 | 16 | 17 |
| Completed | 14 | 15 | 12 | 12 |
| Not completed | 1 | 4 | 4 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 1 |
WOMAC is a disease specific outcome measure for osteoarthritis. It has three subscales assessing pain (5 questions), stiffness (2 questions) and function (15 questions). together the subscales give an overall total score ranging from 0 (worst) to 100 (best; an increase in total score indicates an improvement in health. THe outcome was measured at baseline, week 8 and week 16. In this study the primary outcome was the reduction in WOMAC total score from baseline to the end of treatment at week 16.
No measurements were reported for this outcome.
Subscale assessed by 100mm VAS based on five questions addressing pain in osteoarthritis using the terminators no pain (0mm) to extreme pain (100mm). a higher score therefore indicates more severe pain. This outcome was recorded at baseline, week 8 and week 16 (end of treatment). The outcome for this study was reported as the change in WOMAC pain score from baseline to end of treatment at week 16.
No measurements were reported for this outcome.
Subscale assessed by 100mm VAS based on twelve questions addressing disability in osteoarthritis with a higher score indicating worse symptoms. The VAS used terminators of no disability (0mm) to extreme disability (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.
No measurements were reported for this outcome.
Subscale assessed by 100mm VAS based on two questions addressing stiffness in osteoarthritis;a higher score indicating worse symptoms. The VAS used terminators of no stiffness (0mm) to extreme stiffness (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.
No measurements were reported for this outcome.
Quality of Life assessment containing 8 scales clustered into 2 summary scales: physical health and mental health. Each question is scored out from 0 (indicating worst health) to 100 (indicating best health). Mean scores for the 8 scales (total scores/no questions completed) are calculated to give a total score for each of the two summary scales between 0 (worst health) and 100 (best health). SF36 was recorded at baseline, week 8 and at the end of treatment at week 16. we reported the change from baseline to end of treatment as the outcome.
No measurements were reported for this outcome.
To assess changes in the subject's well-being based on 7 point likert scale ranging from very poor (0 point) to very good (7 point). Outcome was recorded at baseline, week 8 and end of treatment at week 16. We reported outcome as the change in patient global assessment from baseline to end of treatment at week 16.
No measurements were reported for this outcome.
Questionnaire to assess changes in attitudes and health beliefs to CAM.the questionnaire as 17 questions, each scored on a 7 point likert scale from strongly disagree to strongly agree; a higher score indicates stronger belief in the measure. Minimum score 17, maximum score 119
No measurements were reported for this outcome.
To identify Group differences between the number of adverse event recorded by patient for both serious and non serious adverse events, as well as events considered being attributable to the study medication.
No measurements were reported for this outcome.
Collected over Twenty week period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 240mg Devil Claw | — | 0/15 (0%) | 15/15 (100%) |
| 960mg/d Devil Claw | — | 1/19 (5.3%) | 18/19 (94.7%) |
| 1,920mg/d Devil Claw | — | 0/16 (0%) | 15/16 (93.8%) |
| Placebo | — | 0/17 (0%) | 16/17 (94.1%) |
| Event | 240mg Devil Claw | 960mg/d Devil Claw | 1,920mg/d Devil Claw | Placebo |
|---|---|---|---|---|
| Transient blindnessEye disorders | 0/15 | 1/19 | 0/16 | 0/17 |
| Event | 240mg Devil Claw | 960mg/d Devil Claw | 1,920mg/d Devil Claw | Placebo |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/15 | 11/19 | 9/16 | 11/17 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 6/15 | 7/19 | 2/16 | 2/17 |
| HeadacheGeneral disorders | 5/15 | 5/19 | 3/16 | 2/17 |
| DiarrhoeaGastrointestinal disorders | 3/15 | 4/19 | 1/16 | 1/17 |
| FatigueGeneral disorders | 1/15 | 4/19 | 1/16 | 2/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/15 | 4/19 | 2/16 | 1/17 |
| Back painMusculoskeletal and connective tissue disorders | 2/15 | 2/19 | 3/16 | 3/17 |
| Age, Categorical(Participants) | 240mg Devil Claw | 960mg/d Devil Claw | 1,920mg/d Devil Claw | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 13 | 11 | 9 | 39 |
| >=65 years | 9 | 6 | 5 | 8 | 28 |
| Age Continuous(years) | 240mg Devil Claw | 960mg/d Devil Claw | 1,920mg/d Devil Claw | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 65.2 ± 11.9 | 59.6 ± 6.9 | 59.8 ± 8.4 | 63.2 ± 8.6 | 61.8 ± 9.1 |
| Sex: Female, Male(Participants) | 240mg Devil Claw | 960mg/d Devil Claw | 1,920mg/d Devil Claw | Placebo | Total |
|---|---|---|---|---|---|
| Female | 5 | 10 | 8 | 9 | 32 |
| Male | 10 | 9 | 8 | 8 | 35 |
| Region of Enrollment(participants) | 240mg Devil Claw | 960mg/d Devil Claw | 1,920mg/d Devil Claw | Placebo | Total |
|---|---|---|---|---|---|
| United Kingdom | 15 | 19 | 16 | 17 | 67 |
The record gives a start of Dec 2004, a primary completion of Nov 2007 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Harpagophytum procumbens